XGN241220P2500
- 0.05
- 0.000.00%
Exagen Newsroom
Express News | Exagen Reaches 1M Patient Tested Vy AVISE CTD Milestone
Exagen Inc. Achieves Key Milestone With 1,000,000th Patient Tested by AVISE CTD
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Exagen Inc. (NASDAQ:XGN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Exagen Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Express News | Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the Avise® Ctd Platform
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE CTD Platform
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
TD Cowen Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $7
Exagen's Strategic Advancements and Market Potential Drive Buy Rating Amidst Upcoming ADVISE Test Launch
CCORF Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $5
BTIG Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $5
KeyBanc Maintains Exagen(XGN.US) With Hold Rating
Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript Summary
Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript
Exagen | 8-K: Exagen Inc. Reports Third Quarter 2024 Results
Exagen | 10-Q: Q3 2024 Earnings Report
Exagen Reports Q3 EPS (28c), Consensus (29c)
Earnings Flash (XGN) EXAGEN Reports Q3 Revenue $12.5M
Express News | Exagen Inc: Reiterates 2024 Adjusted Ebitda Loss Expectations of Better Than $12 Mln